Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Multitude Therapeutics will provide proprietary T-Moiety linker technologies, co-developed with HySlink, to accelerate the discovery of preclinical ADC candidates (PCCs) and develop more novel bioconjugates for cancer treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: WuXi XDC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 30, 2024
Details:
Under the agreement, OnCusp obtains the exclusive global rights to lead development and commercialization of CUSP06 worldwide outside of Greater China. CDH6 (Cadherin-6 or K-cadherin) is a high-potential ADC target for multiple solid malignancies.
Lead Product(s): CUSP06
Therapeutic Area: Oncology Product Name: CUSP06
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: OnCusp Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 08, 2022